Member Info for Krone

No tweet from Tim re Proactive Investors interview. Too busy finalising deal/a?

Hi RMM - in wholehearted agreement with you!

Tim exudes an air of confidence in respect of both TYK2 and SRA737....sounds to me like deals are being done imminently.

A sprat to catch a mackerel perhaps?

Hi AndyMKD - you mean, ‘The Company notes with interest a paper in the European Respiratory Journal published in 2017, suggesting that TYK2 inhibition might be effective in the treatment of influenza driven secondary bacterial pneumonia. While the Company is not aware of any ongoing studies in this space, this is potentially highly relevant against the backdrop of the Covid-19 pandemic. The Company intends to investigate grant funding opportunities to assess the potential use of its inhibitors to address this threat to global public health’.
All sounded a tad luke warm on the conference call!

https://doi.org/10.1038/s41575-020-0273-0

http://epaper.businessweekly.co.uk/html5/reader/get_clipping.aspx?edid=bc2009ec-f15d-46f1-a6bf-e35aa9a1c659&pnum=23&time=20200327154749977

Andrew Scott of Proactive Investors confirms that he is speaking to Tim soon.....

Ooops missed the previous posts on this.

In this challenging time we all need to do our part to help in the fight against #COVID19. An emerging hypothesis posits that certain JAKi, including momelotinib, may have anti-inflammatory and anti-viral activity in COVID-19. Learn more http://ow.ly/KoMr30qsXnU
https://twitter.com/sierraoncology/status/1243259772679475200?s=19

Num4 - you ain’t wrong there!

Hi RMM - Excellent summary, very many thanks.
I think the early/Late stage pre-clinical/clinical point was laboured and it seemed to me that they were trying to manage expectations towards late stage pre-clinical. So are we now at late stage preclinical with 1801 and a bit behind with 1802?
I didn't get any sense of urgency at all re the potential Covid 19 application - looking for grant funding for what? If they were really serious they would on the blower day and night to Daniel O'Day, WHO and others.
And at the risk of repetition I simply don't buy the 'we are not sighted on Sierra's plans'. CRPF must be and they must be talking to Sareum. The question is how long will Glover play his games?
Link to the presentation - http://www.sareum.com/files/6115/8522/3119/Sareum_Interims_Mar_2020.pdf
Thanks again,
All IMHO and GLA

Interesting paper on TYK2 as a potential treatment for secondary pneumonia. Sareum will look at grant funding options. #coronavirus #COVID19

Surely this warrants a separate RNS?!

'No immediate visibility' maybe but Sareum must be breathing down the necks at ICR!
Sareum remains cautiously optimistic that, based on the promising clinical and preclinical data generated to date, Sierra will find a suitable partner to undertake the future development of SRA737. Sareum has no immediate visibility on the state of progress, nor any terms which might be sought in the on-licensing deal. As a result, the Directors have concluded that the timing of two near-term milestone payments – disclosed by Sierra for the first time in August 2019 and together worth approximately US$5 million to Sareum – is likely to be delayed, and the Board of directors does not currently expect payment during this financial year.

The Company notes with interest a paper in the European Respiratory Journal published in 2017, suggesting that TYK2 inhibition might be effective in the treatment of influenza driven secondary bacterial pneumonia. While the Company is not aware of any ongoing studies in this space, this is potentially highly relevant against the backdrop of the Covid-19 pandemic. The Company intends to investigate grant funding opportunities to assess the potential use of its inhibitors to address this threat to global public health.

Tim and John, us next?
Following this morning’s announcement, we are also pleased to announce the acceleration and re-prioritisation of our proprietary pipeline assets as a result of significant strengthening of the Company’s balance sheet. Read more about this R&D update here: silence-therapeutics.com/media/2013/200…

Silence Therapeutics - Stephen Parker ex Chairman

We are thrilled to announce the collaboration between Silence Therapeutics and @AstraZeneca to discover, develop and commercialise #siRNA therapeutics for #cardiovascular, #renal, #metabolic and #RespiratoryDiseases. Read more on the announcement here: silence-therapeutics.com/media/2012/sil…

Num4, thanks, we have data in respect of 1801, pending publication once the DoD give the nod. JR said in December that the data would be published ‘in the near future’.

Hi RMM - thanks once again. Just getting a tad jittery and hope the confidence that was evidenced at the AGM is reiterated in the upcoming update.